Hepatitis E Virus Infection in Patients with Chronic Inflammatory Bowel Disease Treated with Immunosuppressive Therapy.
hepatitis E
immunomodulators
intestinal bowel disease
Journal
Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317
Informations de publication
Date de publication:
15 Feb 2023
15 Feb 2023
Historique:
received:
09
01
2023
revised:
06
02
2023
accepted:
14
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Medical treatment of inflammatory bowel disease (IBD) has evolved significantly, and treatment with immunomodulators is recommended. These medications may alter the patient's immune response and increase the risk of opportunistic infections. Our aim was to evaluate the prevalence and the incidence of acute or chronic HEV infection in IBD patients under immunomodulatory treatment. We conducted a retrospective, multicenter, observational study between 2017 and 2018. IBD outpatients hospitalized for the infusion of immunomodulators were included in 16 French centers. During their daily hospitalization, blood samples were drawn for HEV serology (IgM and IgG) and HEV RNA detection. A total of 488 patients were included, of which 327 (67%) patients had Crohn's disease and 161 (33%) ulcerative colitis. HEV IgM was detected in 3 patients, but HEV RNA was undetectable in all patients. The HEV IgG seroprevalence rate was 14.2%. IgG-positive patients were older at sampling ( Systematic screening for HEV infection is not needed among IBD patients on immunomodulatory medications. However, in the event of abnormal liver test findings, HEV should be part of the classic diagnostic assessment.
Sections du résumé
BACKGROUND
BACKGROUND
Medical treatment of inflammatory bowel disease (IBD) has evolved significantly, and treatment with immunomodulators is recommended. These medications may alter the patient's immune response and increase the risk of opportunistic infections. Our aim was to evaluate the prevalence and the incidence of acute or chronic HEV infection in IBD patients under immunomodulatory treatment.
PATIENTS AND METHODS
METHODS
We conducted a retrospective, multicenter, observational study between 2017 and 2018. IBD outpatients hospitalized for the infusion of immunomodulators were included in 16 French centers. During their daily hospitalization, blood samples were drawn for HEV serology (IgM and IgG) and HEV RNA detection.
RESULTS
RESULTS
A total of 488 patients were included, of which 327 (67%) patients had Crohn's disease and 161 (33%) ulcerative colitis. HEV IgM was detected in 3 patients, but HEV RNA was undetectable in all patients. The HEV IgG seroprevalence rate was 14.2%. IgG-positive patients were older at sampling (
CONCLUSION
CONCLUSIONS
Systematic screening for HEV infection is not needed among IBD patients on immunomodulatory medications. However, in the event of abnormal liver test findings, HEV should be part of the classic diagnostic assessment.
Identifiants
pubmed: 36839604
pii: pathogens12020332
doi: 10.3390/pathogens12020332
pmc: PMC9966788
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Indian J Gastroenterol. 1991 Jul;10(3):96-100
pubmed: 1916971
World J Gastroenterol. 2016 Aug 21;22(31):7030-45
pubmed: 27610014
Gastroenterology. 2011 May;140(5):1481-9
pubmed: 21354150
Hepatology. 2017 Jan;65(1):388-389
pubmed: 27617933
Medicine (Baltimore). 2015 Apr;94(14):e675
pubmed: 25860212
Inflamm Bowel Dis. 2015 Dec;21(12):2848-56
pubmed: 26273817
J Hepatol. 2007 Mar;46(3):387-94
pubmed: 17125878
Gastroenterol Hepatol. 2016 Mar;39(3):185-90
pubmed: 26257097
J Crohns Colitis. 2020 Jan 1;14(1):4-22
pubmed: 31711158
Eur J Gastroenterol Hepatol. 2016 Jul;28(7):786-91
pubmed: 27015138
PLoS One. 2020 Oct 7;15(10):e0239825
pubmed: 33027305
Am J Gastroenterol. 2007 Feb;102(2):344-50
pubmed: 17100965
J Viral Hepat. 2016 Feb;23(2):68-79
pubmed: 26344932
Liver Int. 2018 Sep;38(9):1536-1546
pubmed: 29788538
Transbound Emerg Dis. 2019 Nov;66(6):2462-2473
pubmed: 31336031
Gut. 2019 Dec;68(Suppl 3):s1-s106
pubmed: 31562236
Emerg Infect Dis. 2012 May;18(5):869-72
pubmed: 22516170
Hepatology. 2016 Apr;63(4):1145-54
pubmed: 27008201
Med Klin (Munich). 2010 Apr;105(4):305-9
pubmed: 20455055
Viruses. 2019 Feb 22;11(2):
pubmed: 30813268
PLoS One. 2022 Aug 5;17(8):e0272809
pubmed: 35930611